GoodRx Holdings, Inc.

What does GoodRx own?
GoodRx owns a portfolio of digital healthcare brands and services. These include the core GoodRx platform for prescription drug price comparison and discount coupons, GoodRx Gold (subscription service for enhanced savings), GoodRx Care (telehealth platform), GoodRx for Weight Loss (condition-specific subscription for GLP-1 treatments), and initiatives including RxSmartSaver and Community Link. The company does not own pharmacies or pharmaceutical manufacturers but partners with them.

Is GoodRx publicly traded?
Yes, GoodRx Holdings, Inc. is publicly traded on the Nasdaq stock exchange under ticker GDRX. The company went public in September 2020, raising approximately $1.1 billion in its IPO. GoodRx has a dual-class share structure with 108.6 million Class A shares and 234.0 million Class B shares as of February 2026. Class B shares carry ten votes per share, giving founders and early investors disproportionate voting control. The market value of non-affiliate shares was approximately $423.2 million as of June 2025.

Who is the CEO of GoodRx?
Wendy Barnes has served as President and CEO of GoodRx since January 1, 2025. She succeeded Interim CEO Scott Wagner. Barnes has over 30 years of experience in the pharmacy and medical benefit industry, including roles as CEO of RxBenefits (2022 to 2024) and President of Express Scripts Pharmacy (2019 to 2022). She holds a B.S. in Biochemistry from the United States Air Force Academy and an MBA from the University of Alaska Anchorage.

Who founded GoodRx?
GoodRx was founded in 2011 by Trevor Bezdek, Doug Hirsch, and Scott Borchert in Santa Monica, California. The founders recognized that prescription drug prices vary widely between pharmacies and built a platform to help consumers compare prices and access discount coupons. Bezdek serves as Chairman of the Board. The founders wanted to make healthcare more affordable for Americans.

Where is GoodRx headquartered?
GoodRx is headquartered in Santa Monica, California, USA. The company has been based in Santa Monica since its founding in 2011. GoodRx operates primarily in the United States, with approximately 1,000 employees. The company does not have international operations.

What is GoodRx's revenue?
GoodRx reported FY2025 revenue of $796.9 million, up 1 percent from $792.3 million in FY2024. Net income was $30.4 million, and adjusted EBITDA was $270.5 million with a 33.9 percent margin. Revenue is divided into prescription transactions ($544.0 million), pharma direct ($151.4 million, up 41 percent), and subscriptions ($83.8 million). For FY2026, GoodRx guided to revenue of $750 to $780 million, representing a 2 to 6 percent decline.

What was the FTC action against GoodRx?
In February 2023, the FTC filed an enforcement action against GoodRx for sharing users' sensitive health information with Facebook, Google, and Criteo for advertising purposes, despite promising users it would never share such data. GoodRx agreed to pay a $1.5 million civil penalty and stop sharing health data with third parties for advertising. A related class action lawsuit resulted in a revised $32 million settlement in December 2025. The FTC's action was the first enforcement under its Health Breach Notification Rule.

GoodRx was founded in 2011 by Trevor Bezdek, Doug Hirsch, and Scott Borchert in Santa Monica, California. The founders recognized that prescription drug prices in the United States vary widely between pharmacies and that most consumers had no way to compare prices. They built a website and mobile app that aggregated prescription prices and offered discount coupons to consumers for free.

The company grew through partnerships with pharmacies and pharmacy benefit managers (PBMs). GoodRx partnered with over 70,000 pharmacies across the United States to offer discounts to consumers. The company made money by receiving a fee from PBM partners each time a consumer used a GoodRx coupon at a pharmacy. The service gained traction through word-of-mouth and digital marketing, particularly among consumers without insurance or with high-deductible health plans.

In 2015, GoodRx launched GoodRx Gold, a subscription service offering additional savings on prescriptions and access to discounted mail-order options. The subscription model provided recurring revenue and deeper discounts for frequent prescription users.

GoodRx went public in September 2020 on the Nasdaq stock exchange under ticker GDRX. The IPO raised approximately $1.1 billion. The company's stock debuted at $33 per share and traded above $50 at its peak in 2021, giving GoodRx a market capitalization exceeding $19 billion at its height. The stock has since declined significantly, trading around $4 to $5 per share in 2025 and 2026.

The company expanded into telehealth with the acquisition of HeyDoctor (later rebranded as GoodRx Care), which provides online medical consultations and prescription delivery. GoodRx also added healthcare provider search capabilities and integrated savings programs with partners.

In 2025, GoodRx launched condition-specific subscription offerings for weight loss, erectile dysfunction, and hair loss. GoodRx for Weight Loss helps patients access GLP-1 treatments with transparent pricing, targeting a category where insurance coverage remains limited. The company also introduced RxSmartSaver and Community Link initiatives to align incentives across pharmacies, manufacturers, and consumers.

The Rite Aid bankruptcy in 2024 and 2025 reduced GoodRx's prescription transaction volume, as Rite Aid store closures eliminated points of sale for GoodRx coupons. This was a significant factor in the 6 percent decline in prescription transactions revenue in FY2025.

GoodRx has faced significant regulatory and legal challenges related to data privacy, most notably the FTC enforcement action in 2023.

In February 2023, the FTC filed an action against GoodRx for violating the FTC Act and the Health Breach Notification Rule. The FTC alleged that GoodRx shared sensitive personal health information, including users' prescription medications and health conditions, with third-party advertising companies including Facebook, Google, and Criteo, despite promising users it would never share such information. The FTC also alleged that GoodRx used this data to target users with health-related advertisements on Facebook and Instagram. For example, in August 2019, GoodRx compiled lists of users who had purchased medications for heart disease and blood pressure and uploaded their contact information to Facebook for ad targeting.

GoodRx settled with the FTC, agreeing to pay a $1.5 million civil penalty and to stop sharing user health data with third parties for advertising purposes. The FTC's action was the first enforcement under its Health Breach Notification Rule. GoodRx was also required to implement a comprehensive information security program and obtain biennial assessments from a third party.

A related class action lawsuit was filed against GoodRx, Google, Meta, and Criteo. In June 2025, a federal judge struck down a proposed $25 million settlement between GoodRx and the plaintiffs, calling the deal unjustified. In December 2025, GoodRx agreed to a revised $32 million settlement, $7 million more than the original proposal, which also included Criteo as a settling defendant. The settlement makes it easier for plaintiffs to pursue separate settlements with Google and Meta.

GoodRx has also faced scrutiny over its business model. Some critics argue that GoodRx's discounts are not always lower than insurance copays, and that the company's fees from PBMs ultimately increase drug costs. GoodRx has responded that its platform provides transparency and savings for consumers who are uninsured, underinsured, or facing high deductibles.

The Rite Aid bankruptcy in 2024 and 2025 highlighted GoodRx's dependence on the retail pharmacy landscape. Store closures from Rite Aid and other chains reduced GoodRx's distribution network and contributed to declining prescription transactions revenue.